221 related articles for article (PubMed ID: 10861426)
1. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma.
Ulrich-Pur H; Kornek GV; Raderer M; Haider K; Kwasny W; Depisch D; Greul R; Schneeweiss B; Krauss G; Funovics J; Scheithauer W
Cancer; 2000 Jun; 88(11):2505-11. PubMed ID: 10861426
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
3. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
[TBL] [Abstract][Full Text] [Related]
5. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
[TBL] [Abstract][Full Text] [Related]
6. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Reni M; Passoni P; Panucci MG; Nicoletti R; Galli L; Balzano G; Zerbi A; Di Carlo V; Villa E
J Clin Oncol; 2001 May; 19(10):2679-86. PubMed ID: 11352960
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
[TBL] [Abstract][Full Text] [Related]
8. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V
Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
Penz M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Lenauer A; Depisch D; Krauss G; Schneeweiss B; Scheithauer W
Ann Oncol; 2001 Feb; 12(2):183-6. PubMed ID: 11300321
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
Ulrich-Pur H; Kornek GV; Fiebiger W; Schüll B; Raderer M; Scheithauer W
Oncology; 2001; 60(4):313-5. PubMed ID: 11408798
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
14. Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
Mané JM; Sancho A; Muñoz A; Rubio I; Fernández R; Carrera S; Fuente N; Ballesteros D; Casas R; Marrodán I; Mielgo X; López-Vivanco G
Tumori; 2010; 96(3):405-10. PubMed ID: 20845800
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
16. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study.
Kurtz JE; Kohser F; Négrier S; Trillet-Lenoir V; Walter S; Limacher JM; Untereiner M; Kayitalire L; Jaeck D; Dufour P
Hepatogastroenterology; 2000; 47(35):1450-3. PubMed ID: 11100374
[TBL] [Abstract][Full Text] [Related]
18. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Rothenberg ML; Moore MJ; Cripps MC; Andersen JS; Portenoy RK; Burris HA; Green MR; Tarassoff PG; Brown TD; Casper ES; Storniolo AM; Von Hoff DD
Ann Oncol; 1996 Apr; 7(4):347-53. PubMed ID: 8805925
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
